The first PCSK9 pill is approved. The outcome trial is still running.

Table of Contents

1.0 Summary

On July 17, 2026 the FDA approved Lipfendra (enlicitide), the first PCSK9 inhibitor that comes as a tablet instead of an injection. In two placebo-controlled trials of 3,207 adults already taking the highest statin dose they could tolerate, the once-daily pill lowered LDL cholesterol by an average of 56% in people with or at high risk for cardiovascular disease, and by 59% in people with inherited high cholesterol. Side effects matched placebo in the first trial, while diarrhea and dizziness were more common with the drug in the second. What the approval does not show is whether the pill prevents heart attacks and strokes. The trial designed to answer that, CORALreef Outcomes, has not reported.

2.0 Key Points

  1. The FDA approved enlicitide on July 17, 2026 as an add-on to diet and exercise for adults with high cholesterol, including heterozygous familial hypercholesterolemia.
  2. It is taken once a day by mouth. Every other PCSK9-targeted drug on the market is an injection.
  3. In the two approval trials, LDL cholesterol fell 56% and 59% at 24 weeks compared with placebo, from average starting levels of 96 and 119 mg/dL.
  4. A published review of the phase III CORALreef program reports the reduction held for up to 52 weeks, with adverse event rates similar to placebo.
  5. No trial has yet shown that enlicitide prevents heart attacks, strokes, or death. CORALreef Outcomes is testing that now.

3.0 Evidence base

PCSK9 is a protein that destroys the liver receptors responsible for pulling LDL cholesterol out of the blood. Block it and those receptors survive longer, so the liver clears more cholesterol. Doing that has meant an injection every two weeks or every six months. Enlicitide is a macrocyclic peptide that blocks the same interaction from a tablet taken once a day [2].

The FDA based the approval on two randomized, double-blind, placebo-controlled trials in 3,207 adults, all of them already on the highest statin dose they could tolerate [1]. The first enrolled people with established atherosclerotic cardiovascular disease or a high risk of developing it. Their average starting LDL was 96 mg/dL, and after 24 weeks the drug had lowered it by 56% relative to placebo. The second enrolled people with heterozygous familial hypercholesterolemia, the inherited condition that keeps LDL high from birth. Their average starting LDL was 119 mg/dL and the reduction was 59%.

Side effects were about as common on the drug as on placebo in the first trial. In the second, diarrhea and dizziness came up more often with enlicitide. In both trials, a similar share of people stopped treatment because of side effects whether they were taking the drug or the placebo [1]. A review of the phase III program reports that the LDL reduction, around 60% in the CORALreef Lipids and CORALreef HeFH trials, was still there at 52 weeks [2].

A separate meta-analysis pooled five randomized trials of oral PCSK9 inhibitors as a class, covering 4,268 adults. LDL fell by an average of 49.49 mg/dL against placebo, and triglycerides by 11.65 mg/dL, with further reductions in apolipoprotein B, lipoprotein(a), non-HDL cholesterol, and total cholesterol. Deaths and overall adverse events did not differ from placebo, and fewer people stopped the drug than stopped the placebo [3].

4.0 Where it fits in treatment

Statins remain the starting point, with ezetimibe and the injectable PCSK9 drugs added when someone needs a bigger drop [2]. Enlicitide slots into that same position: an option for the patient who is already on as much statin as they can handle, still has an LDL that is too high, and either will not use an injection or cannot get one covered.

Injections are not the only reason the existing PCSK9 drugs go underused. Cost, access, and inertia in the office all play a part [2], and a pill only solves the first of those. None of the sources behind this article report what enlicitide will cost or how insurers plan to handle it.

For the treatment sequence this site uses, see /clinical/05-treatment-pathways.html. For patients with familial hypercholesterolemia, where the second approval trial was run, see /clinical/07-fh-pathway.html. Drug-by-drug details live in /clinical/10-medication-reference.html.

5.0 Open questions

The approval rests on a surrogate endpoint. Lowering LDL is what a 24-week trial can measure. Preventing a heart attack is what the patient actually wants, and the two are not the same claim. Decades of statin data support the link, but it has to be demonstrated for each drug. CORALreef Outcomes is the trial that will say whether enlicitide does, and it has not reported [2].

Long-term safety is also open. Fifty-two weeks is a short look at a medication someone may take for thirty years [2]. The meta-analysis found no safety signal, but it drew on short trials measuring lipid levels rather than events [3].

One more caution about the numbers above: the 56% and 59% figures come from an FDA press release, not the full trial publication [1]. There are no incidence tables, no confidence intervals, and no breakdown of who dropped out and why. Until the primary papers are published, the effect size is credible and the detail behind it is simply not available yet.

This summary is provided for clinical decision support only and does not replace individualized clinical judgment. Findings are summarized from the cited primary sources; consult those sources before changing practice.

Version History

Version Date Description
1.0.0 2026-08-20 Initial release

References

  1. FDA Approves First Oral PCSK9 Inhibitor to Lower LDL Cholesterol in Adults with High Cholesterol. 2026-07-17. http://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-pcsk9-inhibitor-lower-ldl-cholesterol-adults-high-cholesterol.
  2. Sun Y et al. Enlicitide: The first oral PCSK9 inhibitor approved for treatment of hypercholesterolemia. Drug discoveries & therapeutics. 2026-08-14. doi:10.5582/ddt.2026.01051. Available at: https://doi.org/10.5582/ddt.2026.01051
  3. Khattak MH et al. Efficacy and Safety of Oral PCSK9 Inhibitors in Adults With Hypercholesterolemia: An Updated and GRADE Assessed Systematic Review and Meta-Analysis of Randomised Controlled Trials. Diabetes, obesity & metabolism. 2026-08-10. doi:10.1111/dom.71208. Available at: https://doi.org/10.1111/dom.71208

© 2026 The Sandusky Dyslipidemia Model. For clinical decision support only. Not a substitute for clinical judgment.